Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-06-05 00:00:00 ET · period of report 2025-06-03 · accession 0000935836-25-000416 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-06-05 | 2025-06-03 | STLN | Hively Brad | Dir | S - Sale+OE | $2.87 | -1.98M | 712.0K | -74% | -$5.67M |
| DM | 2025-06-05 | 2025-06-03 | STLN | Hively Brad | Dir | M - OptEx | $0.9008 | +1.87M | 1.40M | New | +$1.68M |
| DM | 2025-06-05 | 2025-06-03 | STLN | Hively Brad | Dir | M - OptEx | $0.00 | +1.87M | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-03 | S | D | 108,532 | $2.87 | 603,501 | D | — | — | (F1) Represents sale of Common Stock acquired from previously vested RSU awards. |
| 2 | Common | Common Stock | 2025-06-03 | S | D | 1,867,605 | $2.87 | 712,033 | D | — | — | |
| 3 | Common | Common Stock | 2025-06-03 | M | A | 946,460 | $0.85 | 2,579,638 | D | — | — | |
| 4 | Common | Common Stock | 2025-06-03 | M | A | 131,297 | $1.87 | 1,633,178 | D | — | — | |
| 5 | Common | Common Stock | 2025-06-03 | M | A | 105,320 | $0.48 | 1,501,881 | D | — | — | |
| 6 | Common | Common Stock | 2025-06-03 | M | A | 684,528 | $0.85 | 1,396,561 | D | — | — | |
| 7 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-06-03 | M | A | 946,460 | $0.00 | 0 | D | $0.85 · — to 2029-12-02 | 946,460 Common Stock | (F6) Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. (F5) These options vested monthly for 48 months following December 2, 2019. |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-06-03 | M | A | 131,297 | $0.00 | 0 | D | $1.87 · — to 2032-11-17 | 131,297 Common Stock | (F6) Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. (F4) These options vested monthly starting November 17, 2022, with cancellation of remaining options pursuant to Note 6 below. |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-06-03 | M | A | 105,320 | $0.00 | 0 | D | $0.48 · — to 2033-03-17 | 105,320 Common Stock | (F6) Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. (F3) These options vested monthly starting March 17, 2023, with cancellation of remaining options pursuant to Note 6 below. |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-06-03 | M | A | 684,528 | $0.00 | 0 | D | $0.85 · — to 2029-12-02 | 684,528 Common Stock | (F6) Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. (F2) These options vested monthly for 36 months following November 12, 2021. |